K&F’s first post-pandemic jury trial resulted in a $10.6 million verdict for the widow of a mesothelioma victim.

Products liability news: Infant ibuprofen recalled

On Behalf of | Dec 11, 2018 | Products Liability

Like other parents in the country, Ohio parents do everything they can to keep their children healthy. When they are not, parents try to make them as comfortable as possible and give them the treatment they need in order to recover. In many households, that means giving infant ibuprofen, but right now, that could put a baby in more danger and lead to a products liability claim.

Tris Pharma, Inc. has voluntarily recalled certain lots of its “Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL.” The products that are subject to the recall could contain higher amounts of ibuprofen than they should. This could cause some infants to suffer from permanent NSAID-associated renal injury.

Ohio parents who give their infants ibuprofen should watch for symptoms such as nausea, epigastric pain and vomiting. Some children may even experience diarrhea. Headaches, gastrointestinal bleeding and tinnitus (ringing in the ears) are also possible. Customers who wonder whether the ibuprofen they give their infants is part of the recall may visit the website of the Food and Drug Administration or contact Tris Pharma. In any case, it might be a good idea to stop using the product until it is known for sure whether it is part of the recall.

No reports of adverse health consequences have been reported as of yet, but that does not mean it will not happen. Parents who suspect their babies suffered harm due to the affected products could benefit from discussing the matter with a products liability attorney. It may be possible to pursue restitution for the medical and other financial losses incurred as a result of this or another defective and dangerous product.

Archives

$120 Million Settlement

To 15,000 Asbestos Victims

$20 Million Verdict

Mesothelioma

$17 Million Verdict

Mesothelioma

$8.2 Million Verdict

Mesothelioma

White Paper Read Now2
White Paper Read Now